Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on April 13, 2005, reporting events occurring on April 7, 2005. The company is incorporated in Florida and operates from New York, New York.
Key Financial Metrics
The filing details a private placement transaction rather than standard operating financials. Key metrics include:
- Aggregate Proceeds: Approximately $2.95 million.
- Securities Issued: 1,515,384 shares of common stock and 378,846 warrants sold as Units.
- Price per Unit: $1.95.
- Transaction Costs: $236,400 cash paid plus 121,231 warrants issued to the selling agent (Axiom Capital Management).
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of new common stock and warrants. The company entered into a Registration Rights Agreement requiring the filing of a registration statement for the resale of these securities within 120 days of January 28, 2005.
Outlook, Risks, and Unusual Items
Warrant Terms: Investor warrants are exercisable at $2.95 per share for five years. Agent warrants are exercisable at $2.15 per share for five years.
Regulatory Status: The sale relied on exemptions under Section 4(2) of the Securities Act and Rule 506, assuming all purchasers are accredited investors.
Unusual Items: The filing text does not provide clear values for revenue, profit, cash flow, margins, or debt levels, as this is a transaction-specific report.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the status of the Registration Rights Agreement and the filing of the required registration statement.
- Review the company's use of the $2.95 million in proceeds to ensure alignment with stated business objectives.
- Check for any subsequent filings regarding the exercise of the 378,846 investor warrants or 121,231 agent warrants.